Show simple item record Rabinovich, Gabriel Adrian 2016-07-01T18:18:56Z 2014-12-18
dc.identifier.citation Rabinovich, Gabriel Adrian; Classification of current anticancer immunotherapies; Impact Journals; Oncotarget; 5; 24; 18-12-2014; 12472-12508
dc.identifier.issn 1949-2553
dc.description.abstract During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.
dc.format application/pdf
dc.language.iso eng
dc.publisher Impact Journals
dc.rights info:eu-repo/semantics/openAccess
dc.subject CANCER
dc.subject.classification Patología
dc.subject.classification Medicina Básica
dc.subject.classification CIENCIAS MÉDICAS Y DE LA SALUD
dc.subject.classification Inmunología
dc.subject.classification Medicina Básica
dc.subject.classification CIENCIAS MÉDICAS Y DE LA SALUD
dc.title Classification of current anticancer immunotherapies
dc.type info:eu-repo/semantics/article
dc.type info:ar-repo/semantics/artículo
dc.type info:eu-repo/semantics/publishedVersion 2016-06-15T19:09:31Z
dc.identifier.eissn 1949-2553
dc.journal.volume 5
dc.journal.number 24
dc.journal.pagination 12472-12508
dc.journal.pais Estados Unidos
dc.journal.ciudad Nueva York
dc.description.fil Fil: Rabinovich, Gabriel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina
dc.journal.title Oncotarget
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/doi/10.18632/oncotarget.2998
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/pmid/PMC4350348
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/doi/
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/url/[]=2998&pubmed-linkout=1
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/url/

Archivos asociados

This item appears in the following Collection(s)

  • Articulos(IBYME) [1050]

Show simple item record

info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution 2.5 Unported (CC BY 2.5)